Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis?

Clin Invest Med. 1995 Apr;18(2):139-43.


The aim of this investigation has been to assess whether gold therapy prevents radiologic progression of psoriatic arthritis (PsA) over a period of 2 y. Eighteen patients (11 males, 7 females, mean age 42 y, DD 6.5 y) who were initiated on intramuscular gold during their attendance at the Psoriatic Arthritis Clinic were studied. For each gold-treated patient, 2 matched control patients, who had never had gold therapy, were identified from the PsA database. The control patients were similar to the patient population in gender, age, disease duration, number of actively inflamed joints, radiologic score and other medications used, and were followed in the clinic for at least 24 months. Actively-inflamed joint count decreased by > or = 40% in 9 of 18 gold-treated patients at 12 months. Seven patients continued gold for 24 months, while 11 discontinued gold for either lack of efficacy (4) or side effects (7). A comparison of the change in radiographic evidence of damage in the peripheral joints between the 18 gold-treated patients and the 36 controls revealed that there was no statistical difference in disease progression. These results suggest that gold therapy does not prevent the progression of damage in patients with psoriatic arthritis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Psoriatic / diagnostic imaging
  • Arthritis, Psoriatic / drug therapy*
  • Arthritis, Rheumatoid / drug therapy
  • Case-Control Studies
  • Chloroquine / therapeutic use
  • Female
  • Humans
  • Male
  • Methotrexate / therapeutic use
  • Middle Aged
  • Organogold Compounds
  • Radiography
  • Steroids / therapeutic use


  • Anti-Inflammatory Agents, Non-Steroidal
  • Antirheumatic Agents
  • Organogold Compounds
  • Steroids
  • Chloroquine
  • Methotrexate